Nanobiotix Shares Dip 2% as It Digests Its Annual Rally of Over 725%
The French biotech continues its decline in early afternoon, despite a boost from a leading analyst. The movement is part of a digestion phase that began after the mid-May historical record. The stock remains well above its 200-day moving average, reflecting the magnitude of the annual rally.
Oddo BHF Raises Target from €31 to €40 and Upgrades to Outperform
Nanobiotix shares are down 2.3% at €30.54 in early afternoon trading, while the SBF 120 is down 0.37%. The stock is among the biggest losers in the index. Oddo BHF raised its price target for the stock from €31 to €40 this Wednesday, and upgraded its recommendation to 'outperform'. The new target represents a potential appreciation of nearly 31% from the current price. The firm joins the movement already started by Jefferies, which had raised its target from €21.50 to €60 on May 22, as noted in the analyst consensus. The upgrade follows the publication of the first quarter 2026 results. The company confirmed a net cash position of €42.1 million as of March 31, after a capital increase of €86.1 million through pre-financed warrants, as detailed in the quarterly publication. The initial phase 2 results of JNJ-1900 (NBTXR3) in inoperable lung cancer showed an objective response in 6 out of 7 patients, from a small cohort.
A Retreat Below the 50-Day MA Extends the Digestion of the Mid-May Rally
The price is below its 50-day moving average (€31.32), with a limited gap of 2.5%. Above, the 20-day MA at €37.54 remains out of immediate reach, indicating that the consolidation phase initiated after the historical peak on May 18 at €47.66 is not yet over. The RSI at 42 indicates a short-term lackluster dynamic, with no oversold signal. Over the week, the decline reaches 13.6%, while the annual performance remains extraordinary, at over 725%. The stock thus maintains a gap of nearly 44% above its 200-day moving average at €21.21, which reflects the extent of the journey made over twelve months. The technical support identified at €26.34 remains the next reference threshold to monitor the ongoing digestion phase.
